MOTS-c gets called “exercise in a bottle.” It is one of the most talked-about longevity peptides right now, and it was one of the six peptides an FDA advisory panel recommended for compounding in July 2026. The science behind it is real and interesting. It is also almost entirely in mice. Native MOTS-c has never been given to people in a published trial.
There are good animal studies and some interesting human observations. When people exercise, their own MOTS-c goes up. But no study has ever tested injecting MOTS-c into humans. The FDA said so directly in its 2026 review. The only human dosing data comes from a modified version called CB4211, and that program was shut down. So the honest summary is promising biology, zero human proof.
MOTS-c is a 16-amino-acid peptide. What makes it unusual is where it comes from. Most of your genes live in the nucleus of your cells. MOTS-c is coded by a tiny stretch of DNA inside your mitochondria, the energy factories of the cell. That puts it in a small family called mitochondrial-derived peptides, alongside one called humanin. The name stands for “mitochondrial open reading frame of the 12S rRNA-c,” which is a mouthful, so everyone just says MOTS-c.
It was described in 2015 by Changhan David Lee, Pinchas Cohen and colleagues at the University of Southern California, in the journal Cell Metabolism. Cohen co-founded a company called CohBar to turn mitochondrial peptides into drugs. CohBar built a modified version, CB4211, and took it into early human trials. Then the company ran out of road. A planned merger fell apart in late 2023 and CohBar moved to wind down. No one has picked the program back up.
Most of what we know comes from cells and mice. MOTS-c seems to act mainly on muscle. It interferes with a metabolic pathway called the folate cycle, which causes a molecule called AICAR to build up. AICAR switches on AMPK, the cell’s main energy sensor. AMPK is the same switch that exercise flips, which is where the “exercise mimetic” idea comes from. The result in mice is better glucose uptake and better insulin sensitivity.
Under stress, MOTS-c also moves into the cell nucleus and helps turn on protective genes. That is a striking finding, because it means a mitochondrial signal is talking back to the nucleus.
One honest caveat. The FDA’s 2026 briefing said the actual molecular target of MOTS-c is still unknown. So the pathway story is well studied, but nobody can point to the exact receptor it binds.
In mice, MOTS-c prevented weight gain and insulin resistance on a high-fat diet, reversed age-related insulin resistance, and improved running capacity in young, middle-aged and old animals.
In people, the data is observational. A 2021 study found exercise raised MOTS-c about 12-fold inside muscle but only about 1.5-fold in the blood. That difference matters, because you will see the “12-fold” number quoted without the context.
The CB4211 trial is the closest thing to human dosing. In a small Phase 1b study of 20 people with obesity and fatty liver, four weeks of daily injections lowered liver enzymes and blood sugar versus placebo. But liver fat dropped about the same amount on drug and placebo, and weight loss was only a “trend.” And CB4211 is a different molecule from what people buy as MOTS-c.
The community uses it for fat loss, insulin sensitivity, endurance and general longevity. These goals come straight from the mouse studies. None has been shown in humans.
There is no human safety data for native MOTS-c by any route. The FDA flagged a risk of immune reactions, since peptides can clump and carry impurities, and injection under the skin makes that more likely. It also noted there is no standard testing for impurities or endotoxin in what is being sold. USADA lists reported effects like a racing heart, palpitations, insomnia, injection-site irritation and fever. Long-term effects are unknown.
Then there is the gray market. A “research use only” vial has no oversight of what is actually in it.
Reporting, not a recommendation. Community and vendor sources describe subcutaneous injections in the range of 5 to 10 mg per dose, one to a few times a week, in cycles of several weeks. No human study backs any of those numbers. The only human dosing was for CB4211 at 25 mg daily, which is a different molecule. We do not give mixing or injection steps.
Not FDA-approved. In 2023 the FDA placed MOTS-c in Category 2, which effectively blocked compounding. In April 2026 it was removed from Category 2 after its nomination was withdrawn. That did not make it legal to compound. It just cleared the way for a fresh review.
At the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA staff recommended against adding MOTS-c to the compounding list. The panel voted to recommend it anyway, 7 yes, 5 no, with 2 abstentions. That vote is not binding. The FDA still has to go through formal rulemaking, and until it does, compounding MOTS-c is not lawful. We explain that process in our post on the “Do Not Compound” list.
For athletes, MOTS-c has been named on the WADA Prohibited List since 2024 as a metabolic modulator, banned at all times.
Is MOTS-c FDA-approved? No. A July 2026 advisory vote recommended allowing compounding, but that is not approval and it is not in effect.
Has it been tested in humans? Not native MOTS-c. Only a modified version, CB4211, in small, short trials.
Does it cause weight loss? In mice, yes. In humans it is unproven.
Is it really “exercise in a bottle”? That overstates it. Exercise raises your own MOTS-c. Injected MOTS-c improved performance in mice only.
Is it banned in sport? Yes. WADA has named it since 2024, at all times.
What are the side effects? There is no controlled data. Reports include injection-site reactions, palpitations, insomnia and immune reactions.
Who discovered it? Lee, Cohen and colleagues at USC, published in 2015.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.